Guotai Junan Securities: Maintains "Buy" rating on Yuenohjai Health (09969.HK) with a target price of HK$26.7.

According to the Wise Wealth Financial APP, Guotai Junan released a research report stating that it has given a "buy" rating to Nuocheng Jianhua (09969.HK), with forecasted revenue for the years 2025-2027 of 1.443/1.859/2.691 billion yuan, representing year-on-year growth of 43/29/45% respectively. Referring to comparable companies, Nuocheng Jianhua was given a 30x PS multiple for the year 2025, with a target price of 24.53/26.70 Hong Kong dollars (exchange rate of 1 Hong Kong dollar = 0.92 RMB). The company's leadership position in the hematology business continues to be solidified with the promotion of products such as obutinib and ICP-248; its multi-pipeline multi-indication drug selinexor has entered Phase III clinical trials.